Ordering Recommendation

May be useful when essential thrombocythemia or idiopathic myelofibrosis is suspected in JAK2 V617F-negative individuals.

New York DOH Approval Status

This test is New York state approved.

Specimen Required

Patient Preparation
Collect

Whole blood or bone marrow in lavender (EDTA).

Specimen Preparation

Whole Blood: Do not freeze. Transport 5 mL whole blood. (Min: 1 mL)
Bone Marrow: Transport 3 mL bone marrow. (Min: 1 mL)

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions

Plasma, serum, FFPE tissue blocks/slides, or frozen tissue. Specimens collected in anticoagulants other than EDTA. Clotted or grossly hemolyzed specimens.

Remarks
Stability

Refrigerated: 7 days; Frozen: Unacceptable

Methodology

Capillary Electrophoresis

Performed

Varies

Reported

7-12 days

Reference Interval

Interpretive Data

Refer to report.

Compliance Category

Laboratory Developed Test (LDT)

Note

The test will detect MPL mutations W515K, W515L, W515A, and S505N.

Hotline History

N/A

CPT Codes

81338

Components

Component Test Code* Component Chart Name LOINC
2005546 MPL Results 62948-5
3016757 MPL, Source 31208-2
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • JAK-2 negative MPN diagnosis
  • JAK2 V617 negative testing
  • MPL 1p34
MPL Mutation Detection by Capillary Electrophoresis